Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | TSHR | P16473 | 3/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albuterol SCHEMBL9545560 | 0.93 | ADRB2 (0.72) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Albuterol SCHEMBL2489838 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| (S)-Albuterol SCHEMBL29496690 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| (S)-Albuterol SCHEMBL5881204 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Albuterol SCHEMBL4913 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Levosalbutamol SCHEMBL29361075 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Albuterol SCHEMBL122805 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Levosalbutamol SCHEMBL4003 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Albuterol SCHEMBL121596 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A | |
| Albuterol SCHEMBL10025126 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383155-B2 | Swellable dosage form comprising gellan gum | EGALET A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-8383154-B2 | Swellable dosage form comprising gellan gum | EGALET A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-8349292-B2 | Treatment of allergic otitis media in mammals with Clostridia neurotoxins | SANDERS IRA (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120039969-A1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET A/S | 2012-02-16 | — | — | US | disclosed |
| EP-1758557-B1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET LTD (GB) | 2011-07-13 | — | — | EP | disclosed |
| EP-2258349-A2 | Swellable dosage form comprising gellan gum | Egalet A/S (DK) | 2010-12-08 | — | — | EP | disclosed |
| US-20080299199-A1 | Swellable Dosage Form Comprising Gellan Gum | EGALET A/S | 2008-12-04 | — | — | US | disclosed |
| EP-1758557-A2 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | Egalet A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005107713-A2 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET A/S (DK) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039969-A1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | PUF60, COG6, GP6 | ADRB2 4710/4885ADRB1 4443/4885CYP1A2 1957/4885 |
| US-20080299199-A1 | Swellable Dosage Form Comprising Gellan Gum | GP6, PUF60, SELL | ADRB2 4697/4885ADRB1 4430/4885CYP1A2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.